Urinary Bladder, Overactive
Conditions
Keywords
Overactive bladder, Solifenacin suspension, Pharmacokinetics, Single-dose, Pediatric
Brief summary
This single-dose study will investigate how well solifenacin suspension is taken up, how long it stays in the body and how well it will be tolerated in children and adolescents aged 5-17 years with symptoms of overactive bladder.
Detailed description
This is a multicenter, open-label, sequential, single ascending dose study. The study will consist of three treatment groups in children and three treatment groups in adolescents, targeting equivalent exposure to the 2.5, 5 and 10 mg doses o.d. in adults at steady state. The study will be conducted in pediatric OAB patients to establish the single-dose PK and the acute safety profile of solifenacin aqueous suspension. Each of the six groups will consist of at least six patients. The study will start with the lowest dose group in adolescent patients (12 to 17 years). When this group has completed the study, their safety and concentration data will be reviewed by a Safety Review Committee. If no safety concerns are evident according to pre-specified criteria, enrollment of children (5 to 11 years) in the lowest dose group and adolescents in the intermediate dose group will be started simultaneously. When these groups have completed the study, their safety data and drug concentration data will also be reviewed. If no safety concerns occurred, enrollment of children in the intermediate dose group and of adolescents in the highest dose group will be started simultaneously. Finally, after these groups completed the study and no safety concerns occurred during associated data review, enrollment of children in the highest dose group will start. Interim review of plasma exposure at lower doses will be used to adjust the next higher doses administered, if necessary.
Interventions
DRUGSolifenacin succinate suspension 2.5 mg
Adolescents and children are given a single dose of solifenacin succinate liquid suspension orally via syringe in the morning of day 1 followed by a glass of water. Doses are calculated per weight of the participant, targeting to have equivalent doses of 2.5 mg of solifenacin once daily in adults.
Adolescents and children are given a single dose of solifenacin succinate liquid suspension orally via syringe in the morning of day 1 followed by a glass of water. Doses are calculated per weight of the participant, targeting to have equivalent doses of 5 mg dose of solifenacin once daily in adults.
DRUGSolifenacin succinate suspension 10 mg
Adolescents and children are given a single dose of solifenacin succinate liquid suspension orally via syringe in the morning of day 1 followed by a glass of water. Doses are calculated per weight of the participant, targeting to have equivalent doses 10 mg dose of solifenacin once daily in adults.
Sponsors
Astellas Pharma Inc
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
5 Years to 17 Years
Healthy volunteers
No
Inclusion criteria
* Symptoms of urgency, diagnosed as OAB according to International Children's Continence Society (ICCS) criteria * Daytime urgency incontinence at least once/day
Exclusion criteria
* Daytime voiding frequency less than 5 * Uroflow indicative of pathology other than OAB * Maximum voided volume \> age expected capacity (\[age +1\] x 30) in ml * Post voiding residual (PVR) \> 10% of the functional bladder capacity * Monosymptomatic enuresis * Congenital anomalies of the genito-urinary tract or nervous system * Current constipation (when treated the patient can enter the study) * Current urinary tract infection (patient will be eligible for enrolment 14 days after a negative dipstick test, provided a second dipstick test, performed after these 14 days, is also negative) * Serum creatinine more than or equal to 2 times the upper limit of normal (ULN) * Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) more than or equal to 2 times ULN, or bilirubin more than or equal to 1.5 times ULN
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Apparent Volume of Distribution During the Terminal Phase (Vz/F) | Day 1 predose up to Day 7 postdose |
| Area Under the Concentration-time Curve from the Time of Dosing Until the Last Measurable Concentration (AUClast) | Day 1 predose up to Day 7 postdose |
| Apparent Total Body Clearance (CL/F) | Day 1 predose up to Day 7 postdose |
| Maximum Concentration (Cmax) | Day 1 predose up to Day 7 postdose |
| Area Under the Concentration-time Curve Extrapolated to Infinity (AUCinf) | Day 1 predose up to Day 7 postdose |
| Apparent Terminal Elimination Half-life (t1/2) | Day 1 predose up to Day 7 postdose |
| Time to Attain Cmax (tmax) | Day 1 predose up to Day 7 postdose |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change from baseline in postvoid residual (PVR) volume | Baseline (screening) and 4 hours postdose | PVR volume is assessed by ultrasonography or bladder scan. |
| Number of Participants with Adverse Events (AEs) | From the first dose of study drug up to 7 days postdose | Safety is monitored by collecting AEs, which includes abnormal laboratory tests, vital signs or ECG data that are defined as an AE if the abnormality induces clinical signs or symptoms, requires active intervention, interruption or discontinuation of study medication or is clinically significant in the investigator's opinion. A treatment-emergent adverse event (TEAE) is defined as an AE that occurs or worsens after study drug administration. A serious AE (SAE) is any untoward medical occurrence that, at any dose: Results in death, is life-threatening, results in persistent or significant disability/incapacity, results in congenital anomaly, or birth defect, requires inpatient hospitalization or leads to prolongation of hospitalization or other medically important events. |
Countries
Belgium, Denmark, Sweden, United Kingdom
Outcome results
None listed